Selegiline is a selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson’s disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. It is grouped under the following drug class(es): Dopamine agents and Serotonin agents. Its therapeutic use is listed as antidepressants, antiparkinsonian agents and central nervous system (CNS) agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include L-Deprenalin, (-)-selegiline, 14611-51-9 and L-Deprenyl. Its PubChem CID is 26757.
Selegiline
| CAS No | 14611-51-9 |
|---|---|
| Molecular Formula | C13H17N |
| Molecular Weight | 187.28 g/mol |
| Synonyms | (2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Selegiline is a selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy.
The listed CAS number is 14611-51-9.
The listed molecular formula is C13H17N.
The listed molecular weight is 187.28 g/mol.
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine.
The source lists L-Deprenalin, (-)-selegiline, 14611-51-9 and L-Deprenyl.